ANTIPLATELET DRUGS MARKET ANALYSIS

Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI2190
Pages :185
Formats :
Excel and PDF
Industry : Pharmaceutical

Antiplatelet Drugs MarketSize and Trends

Global antiplatelet drugs market is estimated to be valued at US$ 2,153.4 million in 2022 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2030).

Figure 1. Global Antiplatelet Drugs Market Share (%), by Mode of Administration, 2022

Increasing incidence of cardiovascular diseases is expected to drive growth of the antiplatelet drugs market.

Increasing incidence of cardiovascular diseases is expected to drive the market growth over the forecast period. Increasing prevalence of cardiovascular disorders, growing geriatric population, and sedentary lifestyle are some of the major factors driving the global antiplatelet drugs market growth. Cardiovascular diseases are the principal cause of death in the developed and emerging economies.

Rise in research & development activities for development of antiplatelet drugs is expected to drive the market growth during the forecast period.

Increasing research and development activities by key players in market for development of antiplatelet drugs is expected to drive the market growth over the forecast period.